ReviewCells2021
Recent Advances in Adipose Tissue Dysfunction and Its Role in the Pathogenesis of Non-Alcoholic Fatty Liver Disease.
Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 49 citations in OpenAlex.
- Subcutaneous Fat Density Is an Independent Predictor of Adverse Outcomes and Shows Early Improvement After Liver Transplantation.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Chronic viral infection aggravates white adipose tissue dysfunction and liver pathology in obesity.Molecular metabolism · 2026Article
- Review
- Association of a novel Fat-Muscle-BMI Index (FMBI) with NAFLD, liver fibrosis, and atherosclerotic cardiovascular disease risk: a cross-sectional study in 1,592 Chinese adults.BMC gastroenterology · 2026Article
- A Synbiotic of Lacto-Nutrients · 2026Article
- Exercise as a Molecular Therapeutic Tool in MASLD: From Signaling Pathways to Clinical Translation-A Narrative Review.Biomedicines · 2026Review
- Fermented Milk as an Alternative Therapy for Obesity.International journal of food science · 2026Review
- Silent inflammation: a hidden cause of liver fibrosis.Frontiers in pharmacology · 2026Review
- GATA-Biology · 2025Article
- R-spondin 2 suppresses hepatic steatosis via activation of AMPK-ACC signaling.JHEP reports : innovation in hepatology · 2025Article
- CD209a regulates metabolic dysfunction-associated steatotic liver disease development through macrophage STAT3 signaling pathway.Cellular & molecular biology letters · 2025Article
- Markers of body fat, the mediating role of alanine aminotransferase, and their association with the risk of metabolic dysfunction-associated steatotic liver disease.European journal of pediatrics · 2025Article
- The Visceral Adiposity Index and Its Usefulness in the Prediction of Cardiometabolic Disorders.Nutrients · 2025Review
- Macrovascular outcomes and mortality after bariatric surgery in patients with metabolic dysfunction-associated steatotic liver disease, and Type 2 diabetes.Diabetology & metabolic syndrome · 2025Article
- USP24 upregulation stabilizes PKA-Cα to promote lipogenesis, inflammation, and fibrosis during MASH progression.Journal of biomedical science · 2025Article
- Possible association between metabolic dysfunction-associated steatotic liver disease predictors and hand grip strength.Scientific reports · 2025Article
- [Research progress on dietary and exercise intervention for the prevention and treatment of non-alcoholic fatty liver disease in obese children].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Review
- HFD feeding for seven months abolishes STING disruption-driven but not female sex-based protection against hepatic steatosis and inflammation in mice.The Journal of nutritional biochemistry · 2025Article
- Hepatocyte-specific loss of melanocortin 1 receptor disturbs fatty acid metabolism and promotes adipocyte hypertrophy.International journal of obesity (2005) · 2024Article
- Melatonin Alleviates Liver Mitochondrial Dysfunction in Leptin-Deficient Mice.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
Obesity is a serious ongoing health problem that significantly increases the incidence of nonalcoholic fatty liver disease (NAFLD). During obesity, adipose tissue dysfunction is obvious and characterized by increased fat deposition (adiposity) and chronic low-grade inflammation. The latter has been implicated to critically promote the development and progression of NAFLD, whose advanced form non-alcoholic steatohepatitis (NASH) is considered one of the most common causes of terminal liver diseases. This review summarizes the current knowledge on obesity-related adipose dysfunction and its roles in the pathogenesis of hepatic steatosis and inflammation, as well as liver fibrosis. A better understanding of the crosstalk between adipose tissue and liver under obesity is essential for the development of new and improved preventive and/or therapeutic approaches for managing NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.